Back to News & Events

IBNY 08 Open Call for Applications

IndieBio NY is hosting an open call for consideration to be a part of its upcoming Spring 2024 Class 08 Cohort. If you are a founder building an early stage pre-seed biotech company that addresses a pressing human and planetary health problem, this may be for you.

Applications can be submitted at the link by January 19th, 2024. Selected companies will be notified as soon as possible and pitches will be scheduled for the first week of February with virtual and in person options available: https://airtable.com/app4sqweetYmYsYct/shrnu4JPt2y86CDtv

IndieBio is the world’s largest seed life sciences development program devoted to funding and building startups to solve humanity’s most pressing problems with life itself. Twice a year, IndieBio selects 10 to 15 early-stage companies across different sectors in the life sciences to partake in an intensive 4-month program in New York City.

Each team is provided with funding, a rent-free lab, co-working space, dedicated educational programming and mentorship, and access to IndieBio’s massive network of alumni, investors, entrepreneurs, press, and corporate partners. Learn more about IndieBio at https://indiebio.co/.

Related Stories

WP_Query Object
(
    [query] => Array
        (
            [post_type] => post
            [posts_per_page] => 3
            [post_status] => publish
            [orderby] => rand
        )

    [query_vars] => Array
        (
            [post_type] => post
            [posts_per_page] => 3
            [post_status] => publish
            [orderby] => rand
            [error] => 
            [m] => 
            [p] => 0
            [post_parent] => 
            [subpost] => 
            [subpost_id] => 
            [attachment] => 
            [attachment_id] => 0
            [name] => 
            [pagename] => 
            [page_id] => 0
            [second] => 
            [minute] => 
            [hour] => 
            [day] => 0
            [monthnum] => 0
            [year] => 0
            [w] => 0
            [category_name] => 
            [tag] => 
            [cat] => 
            [tag_id] => 
            [author] => 
            [author_name] => 
            [feed] => 
            [tb] => 
            [paged] => 0
            [meta_key] => 
            [meta_value] => 
            [preview] => 
            [s] => 
            [sentence] => 
            [title] => 
            [fields] => 
            [menu_order] => 
            [embed] => 
            [category__in] => Array
                (
                )

            [category__not_in] => Array
                (
                )

            [category__and] => Array
                (
                )

            [post__in] => Array
                (
                )

            [post__not_in] => Array
                (
                )

            [post_name__in] => Array
                (
                )

            [tag__in] => Array
                (
                )

            [tag__not_in] => Array
                (
                )

            [tag__and] => Array
                (
                )

            [tag_slug__in] => Array
                (
                )

            [tag_slug__and] => Array
                (
                )

            [post_parent__in] => Array
                (
                )

            [post_parent__not_in] => Array
                (
                )

            [author__in] => Array
                (
                )

            [author__not_in] => Array
                (
                )

            [search_columns] => Array
                (
                )

            [ignore_sticky_posts] => 
            [suppress_filters] => 
            [cache_results] => 1
            [update_post_term_cache] => 1
            [update_menu_item_cache] => 
            [lazy_load_term_meta] => 1
            [update_post_meta_cache] => 1
            [nopaging] => 
            [comments_per_page] => 50
            [no_found_rows] => 
            [order] => 
        )

    [tax_query] => WP_Tax_Query Object
        (
            [queries] => Array
                (
                )

            [relation] => AND
            [table_aliases:protected] => Array
                (
                )

            [queried_terms] => Array
                (
                )

            [primary_table] => wp_posts
            [primary_id_column] => ID
        )

    [meta_query] => WP_Meta_Query Object
        (
            [queries] => Array
                (
                )

            [relation] => 
            [meta_table] => 
            [meta_id_column] => 
            [primary_table] => 
            [primary_id_column] => 
            [table_aliases:protected] => Array
                (
                )

            [clauses:protected] => Array
                (
                )

            [has_or_relation:protected] => 
        )

    [date_query] => 
    [request] => SELECT SQL_CALC_FOUND_ROWS  wp_posts.ID
					 FROM wp_posts 
					 WHERE 1=1  AND wp_posts.post_type = 'post' AND ((wp_posts.post_status = 'publish'))
					 
					 ORDER BY RAND()
					 LIMIT 0, 3
    [posts] => Array
        (
            [0] => WP_Post Object
                (
                    [ID] => 4439
                    [post_author] => 3
                    [post_date] => 2024-07-30 15:29:07
                    [post_date_gmt] => 2024-07-30 19:29:07
                    [post_content] => 

CFB Client, IAMBIC has been awarded approximately $1M in grant funding from the National Science Foundation Small Business Innovation Research program. IAMBIC is an innovative shoe company disrupting the centuries-old footwear industry with their sizeless, precision-fit footwear driven by proprietary AI algorithms. This substantial funding from NSF enables IAMBIC to scale its cutting-edge precision-fit shoe design and manufacturing.

The Center for Biotechnology and its accelerator programs have been instrumental in assisting IAMBIC with their SBIR pursuits and commercialization development.

Read more about IAMBIC and their recent funding here.

[post_title] => CFB Client IAMBIC Receives $1 Million NSF SBIR Phase II Grant [post_excerpt] => This substantial funding from NSF enables IAMBIC to scale its operations. [post_status] => publish [comment_status] => closed [ping_status] => closed [post_password] => [post_name] => iambic-receives-1-million-nsf-sbir-phase-ii-grant [to_ping] => [pinged] => [post_modified] => 2024-11-19 10:50:15 [post_modified_gmt] => 2024-11-19 15:50:15 [post_content_filtered] => [post_parent] => 0 [guid] => https://centerforbiotechnology.org/?p=4439 [menu_order] => 0 [post_type] => post [post_mime_type] => [comment_count] => 0 [filter] => raw ) [1] => WP_Post Object ( [ID] => 1358 [post_author] => 3 [post_date] => 2015-01-28 16:48:44 [post_date_gmt] => 2015-01-28 16:48:44 [post_content] => Traverse Biosciences, founded by the Center's first appointed BioEntrepreneur-in-Residence Joseph Scaduto, was just awarded a $205,709, Phase I Small Business Technology Transfer (STTR) Award in Partnership with the School of Dental Medicine at Stony Brook University, to evaluate the effectiveness of the company's lead drug candidate for the treatment of periodontal disease. This is the second Phase I STTR award for Traverse Biosciences this year. The research will be led by Lorne Golub, DMD, MD (Honorary) in the Department of Oral Biology and Pathology, and Ying Gu, PhD, DDS, in the Department of General Dentistry, who will serve as co-principle investigators on the award, in close collaboration with Traverse Biosciences. "I congratulate Traverse Biosciences on securing a second STTR award to advance their product development and commercialization efforts," stated Dr. Clinton Rubin, Director of the New York State Center for Biotechnology at Stony Brook University. He added, "STTR funding represents a significant milestone for graduates of our burgeoning BioEntrepreneur-in-Residence program, which is meant to impact the innovation economy and entrepreneurial ecosystem in the region." A full press release can be found here: http://www.traversebiosciences.com/pr150126perio.html TraverseBioLogo2 [post_title] => Traverse Biosciences receives $205,709 Phase I STTR Award [post_excerpt] => Traverse Biosciences, founded by the Center's first appointed BioEntrepreneur-in-Residence Joseph Scaduto, was just awarded a $205,709, Phase I Small Business Technology Transfer (STTR) Award in Partnership with the School of Dental Medicine at Stony Brook University [post_status] => publish [comment_status] => open [ping_status] => open [post_password] => [post_name] => traverse-biosciences-receives-205709-phase-i-sttr-award [to_ping] => [pinged] => [post_modified] => 2023-05-13 16:06:32 [post_modified_gmt] => 2023-05-13 16:06:32 [post_content_filtered] => [post_parent] => 0 [guid] => http://centerforbiotechnology.org/new/?p=1358 [menu_order] => 216 [post_type] => post [post_mime_type] => [comment_count] => 0 [filter] => raw ) [2] => WP_Post Object ( [ID] => 3811 [post_author] => 4 [post_date] => 2021-08-30 15:39:32 [post_date_gmt] => 2021-08-30 15:39:32 [post_content] =>

The BBCetc “From the Sources’ Mouth,” fall event is a free, virtual 3-day SBIR/STTR training with program managers from 11 federal agencies.

Each will present a 30-minute overview of their agency’s mission along with tips for creating a successful proposal. Everyone who attends will have time for Q&A as well as the opportunity to sign up for special one-on-one discussions with agency officers.

1 registration. 3 days. 11 SBIR/STTR agencies. One registration gives you access for all three days. Detailed agenda coming soon so you can choose which presenters you want to see.

Sept. 14, 2021
9:00 am - 5:00 pm (EST)
Granting Agencies
SBA, NIH, NSF, DOC-NOAA, DOE, USDA, NIAD

Sept. 15, 2021
9:00 am - 5:00 pm (EST)
Contracting Agencies
SBA, EPA, BARDA, NASA, DOT, DOEd, CDMRP

Sept. 16, 2021
9:00 am - 5:00 pm (EST)
DOD & Components
DOD, DHA, DARPA, SPARTN, NavSea, Air Force/AFWERX, DHS

Register Now

[post_title] => “From the Sources’ Mouth" SBIR/STTR training Program [post_excerpt] => [post_status] => publish [comment_status] => closed [ping_status] => closed [post_password] => [post_name] => from-the-sources-mouth-sbir-sttr-training-program [to_ping] => [pinged] => [post_modified] => 2021-09-20 16:03:09 [post_modified_gmt] => 2021-09-20 16:03:09 [post_content_filtered] => [post_parent] => 0 [guid] => https://centerforbiotechnology.org/?p=3811 [menu_order] => 39 [post_type] => post [post_mime_type] => [comment_count] => 0 [filter] => raw ) [3] => WP_Post Object ( [ID] => 3583 [post_author] => 3 [post_date] => 2020-07-16 10:33:42 [post_date_gmt] => 2020-07-16 10:33:42 [post_content] => Long Island Headquartered Enzo Biochem, Inc. and Farmingdale State College have announced they are partnering to provide molecular and antibody testing for COVID-19 to the campus community as the college reopens this summer and begins classes in the fall. LIBMI Mentor & CFB Advisor, Kara Cannon, Enzo’s Chief Commercial Officer commented, “Enzo is launching its School and Institution Testing (“SIT”) Program to ensure well-being, security, and compliance at educational and religious institutions. Farmingdale State College is the first to leverage Enzo’s expertise and enable this academic institution to safely forge a course forward this summer into the fall.” Read the full press release on the partnership here. [post_title] => Enzo & Farmingdale State College Partner on Campus COVID Testing [post_excerpt] => Enzo Biochem, Inc. and Farmingdale State College are partnering to provide testing for COVID-19 to the campus community this fall. [post_status] => publish [comment_status] => open [ping_status] => open [post_password] => [post_name] => enzo-farmingdale-state-college-partner-on-campus-covid-testing [to_ping] => [pinged] => [post_modified] => 2020-09-14 14:22:27 [post_modified_gmt] => 2020-09-14 14:22:27 [post_content_filtered] => [post_parent] => 0 [guid] => https://centerforbiotechnology.org/?p=3583 [menu_order] => 60 [post_type] => post [post_mime_type] => [comment_count] => 0 [filter] => raw ) ) [post_count] => 4 [current_post] => -1 [before_loop] => 1 [in_the_loop] => [post] => WP_Post Object ( [ID] => 4439 [post_author] => 3 [post_date] => 2024-07-30 15:29:07 [post_date_gmt] => 2024-07-30 19:29:07 [post_content] =>

CFB Client, IAMBIC has been awarded approximately $1M in grant funding from the National Science Foundation Small Business Innovation Research program. IAMBIC is an innovative shoe company disrupting the centuries-old footwear industry with their sizeless, precision-fit footwear driven by proprietary AI algorithms. This substantial funding from NSF enables IAMBIC to scale its cutting-edge precision-fit shoe design and manufacturing.

The Center for Biotechnology and its accelerator programs have been instrumental in assisting IAMBIC with their SBIR pursuits and commercialization development.

Read more about IAMBIC and their recent funding here.

[post_title] => CFB Client IAMBIC Receives $1 Million NSF SBIR Phase II Grant [post_excerpt] => This substantial funding from NSF enables IAMBIC to scale its operations. [post_status] => publish [comment_status] => closed [ping_status] => closed [post_password] => [post_name] => iambic-receives-1-million-nsf-sbir-phase-ii-grant [to_ping] => [pinged] => [post_modified] => 2024-11-19 10:50:15 [post_modified_gmt] => 2024-11-19 15:50:15 [post_content_filtered] => [post_parent] => 0 [guid] => https://centerforbiotechnology.org/?p=4439 [menu_order] => 0 [post_type] => post [post_mime_type] => [comment_count] => 0 [filter] => raw ) [comment_count] => 0 [current_comment] => -1 [found_posts] => 261 [max_num_pages] => 87 [max_num_comment_pages] => 0 [is_single] => [is_preview] => [is_page] => [is_archive] => [is_date] => [is_year] => [is_month] => [is_day] => [is_time] => [is_author] => [is_category] => [is_tag] => [is_tax] => [is_search] => [is_feed] => [is_comment_feed] => [is_trackback] => [is_home] => 1 [is_privacy_policy] => [is_404] => [is_embed] => [is_paged] => [is_admin] => [is_attachment] => [is_singular] => [is_robots] => [is_favicon] => [is_posts_page] => [is_post_type_archive] => [query_vars_hash:WP_Query:private] => 325c4f9f1aebaa5ec90666fa54175ba0 [query_vars_changed:WP_Query:private] => [thumbnails_cached] => [allow_query_attachment_by_filename:protected] => [stopwords:WP_Query:private] => [compat_fields:WP_Query:private] => Array ( [0] => query_vars_hash [1] => query_vars_changed ) [compat_methods:WP_Query:private] => Array ( [0] => init_query_flags [1] => parse_tax_query ) )

CFB Client IAMBIC Receives $1 Million NSF SBIR Phase II Grant

More Information

Traverse Biosciences receives $205,709 Phase I STTR Award

More Information

“From the Sources’ Mouth” SBIR/STTR training Program

More Information

Enzo & Farmingdale State College Partner on Campus COVID Testing

More Information